Clinical trials: Resectable Pancreatic Adenocarcinoma
Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Recurrent
En Bloc Resection of the Liver and Pancreas With a "Non-touch" Technique Followed by Liver Transplantation to Improve the Overall Survival in Patients With Non-resectable Hilar Cholangiocarcinoma Beyond the Mayo Clinic Transplant Criteria
Surgery for hilar cholangiocarcinoma (phCCA) remains a significant challenge. The minority of patients who are eligible for resection are exposed to high procedure-related morbidity and mortality, and despite apparent R0…
- Conditions
- Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Recurrent, Liver Transplantation
- Trial name
- SURE-LT (NCT06850753)
- Testing
- Liver transplantation after en bloc resection of the liver and pancreas
- Where
- Norway
- Volunteers
- 15 people
- Sponsor
- Oslo University Hospital
Pancreatic Neoplasms
FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
This phase I trial studies the side effects and optimal dose of PF-04136309 when given with combination chemotherapy (FOLFIRINOX; 5-fluorouracil, leucovorin, irinotecan, oxaliplatin) in treating patients with locally advanced or…
- Trial name
- NCT01413022
- Testing
- Oxaliplatin, Irinotecan, Leucovorin
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Washington University School of Medicine
Pancreatic Ductal Adenocarcinoma
Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma
The purpose of this study is to determine if study treatment with atezolizumab and PEGPH20 given before and after surgery, followed by chemotherapy is safe and if it can further increase the immune response against the tumor…
- Trial name
- NEOiPANC (NCT03979066)
- Testing
- Atezolizumab, PEGPH20
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Gulam Manji
Localized Non-Resectable Adult Liver Carcinoma
Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study
This research registry studies Yttrium Y 90 resin microspheres in collecting data from patients with liver cancer not capable of being removed by surgery (unresectable) for the radiation-emitting Selective Internal…
- Trial name
- RESiN (NCT02685631)
- Testing
- Yttrium-90 Resin Microspheres
- Where
- 42 sites in United States
- Volunteers
- 1,653 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Adenocarcinoma of the Pancreas
Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma
This will be a phase I/II trial examining the safety and tolerability of pre-operative mFOLFIRINOX in combination with peri-operative oral hydroxychloroquine (FHQ) in the treatment of subjects with adenocarcinoma of the pancreas.
- Trial name
- NCT04911816
- Testing
- Hydroxychloroquine sulfate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- West Virginia University
Locally Advanced Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma
PULSAR in Systemic Therapy for Pancreatic Cancer
Pancreatic cancer remains one of the malignancies with the lowest survival rates, largely due to late-stage diagnosis and the difficulty of achieving curative resection.
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Oligometastatic Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07269626
- Testing
- Personalized Ultrafractionated Adaptive Radiotherapy
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Samsung Medical Center
Locally Advanced Pancreatic Adenocarcinoma, Chemotherapy Effect
Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)
This is a Norwegian prospective observational study that evaluates the resectability rate in patients with borderline resectable and locally advanced pancreatic cancer who received neoadjuvant chemotherapy in a population based…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Chemotherapy Effect, Borderline Resectable Pancreatic Adenocarcinoma, Pancreatectomy
- Trial name
- NCT04423731
- Testing
- Folfirinox
- Where
- Norway
- Volunteers
- 251 people
- Sponsor
- Oslo University Hospital
Pancreatic Cancer Non-resectable
A Phase I Study of Intra-Arterial Yttrium-90 Radioembolization for Unresectable Pancreatic Cancer
This clinical study aims to evaluate the safety and tolerability of intra-arterial Yttrium-90 (90Y) glass microspheres in patients with unresectable pancreatic adenocarcinoma.
- Trial name
- NCT07898683
- Testing
- Transarterial Radioembolization
- Where
- Russia
- Volunteers
- 12 people
- Sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
Pancreatic Cancer
Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
Primary Objective: To assess margin positive resection rate (R1 resection rate; defined as "tumor within 2 mm of surgical margin on final pathology report") in patients treated with preoperative chemotherapy (gemcitabine and…
- Trial name
- NCT00766636
- Testing
- Gemcitabine, Radiation Therapy, Erlotinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Ductal Adenocarcinoma
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
PURPOSE: This phase III clinical trial evaluates the efficacy and safety of adjuvant Immuncell-LC therapy combined with gemcitabine versus adjuvant gemcitabine single therapy after R0 or R1 resection in patients with pancreatic…
- Trial name
- NCT04969731
- Testing
- Immuncell-LC, Gemcitabine
- Where
- South Korea
- Volunteers
- 408 people
- Sponsor
- GC Cell Corporation
Adenocarcinoma of Pancreas
FOLFIRINOX in Patients With Inoperable Pancreatic Cancer
The prognosis of patients with locally advanced unresectable pancreatic cancer is poor, and the median survival is less than 1 year.
- Trial name
- NCT01359007
- Testing
- Irinotecan, Oxaliplatin, Leucovorin, 5-FU
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Oklahoma
Borderline Resectable Pancreatic Ductal Adenocarcinoma
DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer
This clinical trial tests how well dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) with standard clinical evaluation works to assess treatment response for patients with pancreatic cancer that may be able to be…
- Trial name
- NCT07705919
- Testing
- Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8
Intravital Microscopy in Human Solid Tumors
This study will investigate the tumor-associated vasculature of patients with solid tumors. The investigators will use a technology known as intravital microscopy (IVM) in order to visualize in real-time the vessels associated…
- Conditions
- Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma
- Trial name
- NCT03823144
- Testing
- Diagnostic Microscopy, Fluorescein Sodium Injection
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Mayo Clinic
Pancreatic Ductal Adenocarcinoma
Study of NAC of GA Therapy for Patients With BRPC
Gemcitabine plus nub-paclitaxel (GA) regimen was recently presented at an international oncology meeting and represents a new standard regimen in the treatment of metastatic pancreatic cancer.
- Trial name
- NCT02926183
- Testing
- Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel
- Where
- 18 sites in Japan
- Volunteers
- 60 people
- Sponsor
- Wakayama Medical University
Pancreatic Adenocarcinoma Non-resectable, Locally Advanced Pancreatic Adenocarcinoma
FAZA PET/MRI Pancreas
This is a single arm, single centre, investigator initiated study to investigate the use of FAZA-PET in combination with MRI. FAZA is an investigational radiotracer used in PET scans.
- Conditions
- Pancreatic Adenocarcinoma Non-resectable, Locally Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer
- Trial name
- NCT04395469
- Testing
- 18F-FAZA
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Pancreatic Adenocarcinoma
Preoperative Nutrition With Immune Enhancing Nutritional Supplement (Immunomodulation)
The purpose of this study is to determine the optimal effective dose for preoperative nutritional supplementation with immunomodulators on immune function and perioperative outcomes following pancreaticoduodenectomy for…
- Trial name
- NCT02838966
- Testing
- Nestle IMPACT Advanced Recovery, Nestle Boost High Protein Drink
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Louisville
Pancreatic Cancer
Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas
The goal of this clinical research study is to learn if gemcitabine can enter pancreas cancer cells, to measure the amount of it that may enter the cells, and for biomarker testing.
- Trial name
- NCT01276613
- Testing
- Gemcitabine, Losartan
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
This phase II trial evaluates whether early switching from modified fluorouracil/irinotecan/leucovorin/oxaliplatin (mFOLFIRINOX) chemotherapy regimen to a combination of gemcitabine and nab-paclitaxel (GA) before surgery is…
- Conditions
- Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8, Stage III Pancreatic Cancer American Joint Committee on Cancer v8
- Trial name
- NCT04539808
- Testing
- Capecitabine, Fluorouracil, Irinotecan Hydrochloride
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- OHSU Knight Cancer Institute
Pancreas Cancer, Pancreas Neoplasm
Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy
Pancreaticoduodenectomy (PD) is a complex procedure performed in patients with malignant or benign tumors of the pancreatic head and periampullary region, associated with high morbidity and mortality.
- Conditions
- Pancreas Cancer, Pancreas Neoplasm, Pancreatic Fistula, Pancreas Adenocarcinoma
- Trial name
- POPF (NCT07022015)
- Testing
- pancreaticoduodenectomy procedure
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Minia University
Pancreatic Adenocarcinoma
A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma
The purpose of the study is to demonstrate that it is possible to administer chemotherapy prior to and following surgery for pancreatic cancer which is considered operable.
- Trial name
- NCT01660711
- Testing
- 5 Fluorouracil, Leucovorin, Irinotecan
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Endeavor Health